02.22.17
Dr. Marc Hoffman has been appointed chief medical officer at Celerion. Dr. Hoffman will have responsibility for leading the global medical staff and providing medical oversight and expertise to support early clinical research studies. He has more than 28 years of experience as a physician in the pharmaceutical, device, and CRO industries.
Dr. Hoffman previously served as chief medical officer at Patient iP, providing clinical leadership for the company’s platform, customer programs and related medical affairs activities. Prior to Patient iP, he held the roles of chief medical officer and senior vice president and general manager at Theorem Clinical Research. Earlier in his career, Dr. Hoffman held positions of increasing responsibility in medical and scientific affairs at Baxter, Hospira and Covance, providing senior-level strategic direction for Phase II-IV programs.
“We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company,” said Susan Thornton Ph.D., president and chief executive officer. “His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”
Dr. Hoffman previously served as chief medical officer at Patient iP, providing clinical leadership for the company’s platform, customer programs and related medical affairs activities. Prior to Patient iP, he held the roles of chief medical officer and senior vice president and general manager at Theorem Clinical Research. Earlier in his career, Dr. Hoffman held positions of increasing responsibility in medical and scientific affairs at Baxter, Hospira and Covance, providing senior-level strategic direction for Phase II-IV programs.
“We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company,” said Susan Thornton Ph.D., president and chief executive officer. “His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”
